Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Zevra Therapeutics (ZVRA) over the last 5 years, with Q3 2025 value amounting to $30.9 million.

  • Zevra Therapeutics' Long-Term Investments rose 40556.92% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year increase of 40556.92%. This contributed to the annual value of $6.0 million for FY2024, which is N/A changed from last year.
  • Zevra Therapeutics' Long-Term Investments amounted to $30.9 million in Q3 2025, which was up 40556.92% from $15.1 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Long-Term Investments high stood at $33.5 million for Q2 2022, and its period low was $6.0 million during Q4 2024.
  • Its 4-year average for Long-Term Investments is $18.2 million, with a median of $16.3 million in 2022.
  • As far as peak fluctuations go, Zevra Therapeutics' Long-Term Investments soared by 3394.05% in 2022, and later soared by 40556.92% in 2025.
  • Quarter analysis of 4 years shows Zevra Therapeutics' Long-Term Investments stood at $14.9 million in 2021, then soared by 33.94% to $20.0 million in 2022, then tumbled by 69.95% to $6.0 million in 2024, then surged by 413.56% to $30.9 million in 2025.
  • Its last three reported values are $30.9 million in Q3 2025, $15.1 million for Q2 2025, and $6.1 million during Q1 2025.